Blog

Home  /  Activities   /  EUnetHTA Joint Action 3 (2016 - 2020)   /  PTJA13 – EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment.

PTJA13 – EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment.

EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment. PTJA13 addresses ‘satralizumab indicated for the treatment of patients ≥12 years with neuromyelitis optica spectrum disorders (NMOSD)’, submitted by Roche. We are delighted that INFARMED, EUR (Erasmus Universiteit Rotterdam) and ZIN (Zorginstituut Nederland) are authoring this assessment.

We will be issuing an Open Call for Patient Input in due course.